June 7, 2018
Authored and Edited by Y. Leon Lin; Kara A. Specht; Elizabeth D. Ferrill
In UCB Inc., v. Accord Healthcare Inc., the Federal Circuit affirmed the district court’s holding that UCB’s patent on the anti-epileptic drug lacosamide was not rendered obvious by prior art.
The Federal Circuit affirmed the district court’s conclusion that that the patent was distinct from the prior art. The prior art analysis revealed no teachings that render the particular species of combinations claimed obvious, even when the prior art disclosed a broad genus covering the claimed compound generally. The Federal Circuit rejected Appellants’ argument that the presumption of an enabled genus of compounds precludes the finding that there was no reasonable expectation of success of creating a species falling within that genus, stating that such preclusion would create a chilling effect in the chemical arts that would invalidate a compound based on broad genus claims.
The Federal Circuit additionally rejected that the enantiomer lacosamide’s structure had necessarily been revealed by a prior art source that disclosed the chemical structure of the corresponding racemate. Although prior art disclosed the chemical structure of the racemate, it did not disclose its separation into individual enantiomers or data on the separate enantiomers themselves, which the Court found to be patentably distinct.
*Leon Lin is a Summer Associate at Finnegan
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Conference
4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
October 8-24, 2024
Virtual
Conference
2024 Corporate Counsel Women of Color: Career Strategies Conference
October 2-5, 2024
Las Vegas
Seminar
Intellectual Property in the Age of AI: What Do You Own and How Do You Balance Risks?
September 25, 2024
Boston
Webinar
September 10, 2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.